What is Cerebrolysin?

Cerebrolysin is a biological preparation made by enzymatic breakdown of purified porcine (pig) brain proteins, yielding a mixture of low-molecular-weight neuropeptides and free amino acids. It is given by injection, not orally, and is proposed to mimic the brain's own neurotrophic factors.

How does Cerebrolysin work?

It is thought to act like neurotrophic factors (BDNF, CNTF, GDNF-like), modulating the PI3K/Akt and Sonic Hedgehog pathways to support neuron survival and neurogenesis, while reducing excitotoxicity, oxidative stress, and neuroinflammation. Most mechanistic detail comes from animal and in vitro work.

Is Cerebrolysin proven to work?

It is contested. Industry-sponsored trials report benefits for stroke, TBI, and dementia, but independent Cochrane reviews rate the evidence low to very low and find no benefit on all-cause death in stroke. Benefits on cognitive scales exist but their real-world significance is debated.

Is Cerebrolysin safe?

The 2023 Cochrane review found a statistically significant increase in non-fatal serious adverse events (RR 2.39, rising to 2.87 at the 30 mL dose). Anaphylaxis, seizures, and cardiovascular effects are documented. It should only be used under clinical supervision.

Is Cerebrolysin FDA approved?

No. It has no FDA approval for any indication and no legal compounding pathway in the US, despite being a standard of care in over 50 other countries.

How is Cerebrolysin dosed?

It is parenteral only. Standard clinical use is roughly 10 to 20 mL/day; acute stroke or TBI protocols use 30 to 50 mL/day, often divided. Courses typically run 5 days a week for 4 weeks. These are clinical figures, not self-administration guidance.

Who should not use Cerebrolysin?

It is contraindicated in porcine allergy, epilepsy or seizure disorders, and severe renal impairment (GFR < 15 mL/min). It is not recommended in pregnancy or breastfeeding, and caution is needed with antidepressants and MAO inhibitors.

Does the porcine source matter?

Yes, in two ways. It creates allergy and biological-contamination risk, and it raises ethical or religious objections for some traditions. Gray-market product cannot be verified for sterility, purity, or concentration.

Cerebrolysin: Uses, Evidence & Safety

Q: Does the porcine source matter?

Yes, in two ways. It creates allergy and biological-contamination risk, and it raises ethical or religious objections for some traditions. Gray-market product cannot be verified for sterility, purity, or concentration.

For decades the consensus on brain injury was bleak: permanence. Once a stroke or dementia erodes the neuronal network, the window for recovery was thought to close. Against that view sits a controversial contender from Austria that has challenged the status quo for over thirty years.

Cerebrolysin is a porcine-derived injectable marketed as a biological master key for neurorecovery. It exists in a kind of clinical superposition: hailed as a breakthrough in over 50 countries, and dismissed as an unproven compound by the world's most stringent regulators. The truth sits in the gap between those two stories.

Unlike a single synthesized drug, Cerebrolysin is a complex biological mixture. Made only by EVER Neuro Pharma in Austria, it is a proprietary extract from purified porcine brain tissue, produced by enzymatic breakdown of proteins into free amino acids (about 20%) and low-molecular-weight neuropeptides (about 80%).

Mass-spectrometry work has identified fragments of neurotrophic factors including CNTF, GDNF, and IGF-1/IGF-2. This heterogeneity is the whole point of the product, and also its regulatory weakness: it has no single compound identifier and cannot be replicated by another manufacturer.

The biological appeal is that the extract mimics neurotrophic factors, the body's own signals that maintain, protect, and restore neurons. It is proposed to push the brain toward self-repair by modulating survival pathways.

Sonic Hedgehog (Shh): promotes neurogenesis and oligodendrogenesis via Ptch and Smo receptors and the Gli complex (animal/in vitro).
PI3K/Akt: BDNF-like activity that supports cell growth, proliferation, and survival while inhibiting apoptosis.
CREB/PGC-1a: linked to reduced neuroinflammation and lower pro-inflammatory cytokines such as IL-1 beta.

It is also reported to attenuate excitotoxicity, reduce reactive oxygen species, suppress caspase-3-driven apoptosis, lower TNF-alpha and NF-kB signalling, and help stabilise the blood-brain barrier.

Cerebrolysin's clinical record is a tale of two literatures. On one side are large industry-sponsored trials: CASTA (1,070 patients), CARS, and the CAPTAIN series for TBI, which frequently report favourable results for motor recovery and rehabilitation.

On the other side, the independent Cochrane Collaboration tells a different story. Its 2023 update pooled 7 RCTs (1,773 participants) and found no evidence of benefit on all-cause death, alongside a statistically significant increase in non-fatal serious adverse events (Risk Ratio 2.39, rising to 2.87 at the common 30 mL dose). Overall certainty of evidence was rated low to very low.

As of 2026, Cerebrolysin is a standard of care in over 50 nations, including Austria, Russia, China, South Korea, and Germany, for indications like acute ischaemic stroke, TBI, and vascular dementia. In the United States it is a regulatory ghost: no FDA approval for any indication, no New Drug Application, and no legal compounding pathway for human use.

The split is less about safety alone and more about evidentiary thresholds. Fifty countries accept potential benefit and long clinical use; the FDA demands a level of molecular and methodological certainty that a heterogeneous biological mixture may never be able to provide.

Newer work suggests Cerebrolysin is not a magic bullet but a tool that needs the right environment. A 2024 observational cohort by Kojder et al. in subarachnoid haemorrhage found no change in neurological scores for the whole group.

But a nuance emerged: in the severe subgroup (GCS 3 to 8), Cerebrolysin was associated with lower mortality, and only when paired with additional neuromonitoring (ICP, NIRS, EEG). That raises a hard question: is the drug saving lives, or is it an adjuvant to superior intensive care?

Cerebrolysin's biological plausibility is sound: it mimics the very factors that build and repair the brain. Yet the evidence divide remains a chasm between glowing industry trials and cold Cochrane skepticism, and the serious-adverse-event signal cannot be waved away.

The honest position is that biological hope is not the same as clinical proof. Until independent, well-powered data settles the question, Cerebrolysin stays a compound to watch closely and approach cautiously, not a settled therapy, and certainly not one with FDA backing.

Cerebrolysin has a plausible neurotrophic mechanism and a large but industry-weighted trial record. Independent Cochrane reviews find no mortality benefit and a significant non-fatal serious-adverse-event signal (RR 2.39). It is not FDA-approved, is parenteral-only, and carries real risks (anaphylaxis, seizures, gray-market contamination). Treat it as contested and clinician-supervised, not a settled therapy.

PEPTIDE: Cerebrolysin

1.The Quest for Brain Repair

2.A Mixture, Not a Molecule

3.How It Is Proposed to Work

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Related Research

Neuroprotection

Memory Management

Focus / ADHD

Increased Strength

Skin Elasticity

Anxiety / Stress

Stay Ahead of the Research

4.The Evidence Divide

5.A 50-Country Regulatory Schism

6.Why Context Appears to Matter

7.Biological Hope vs Clinical Proof

Bottom line

Frequently Asked Questions